Utah Retirement Systems decreased its holdings in Pfizer Inc. (NYSE:PFE) by 4.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,068,468 shares of the biopharmaceutical company’s stock after selling 46,900 shares during the quarter. Utah Retirement Systems’ holdings in Pfizer were worth $38,710,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. OLD Mission Capital LLC purchased a new stake in shares of Pfizer during the 3rd quarter worth about $291,000. Sage Mountain Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter worth about $261,000. Ironwood Wealth Management LLC. grew its holdings in shares of Pfizer by 1,610.1% during the 4th quarter. Ironwood Wealth Management LLC. now owns 34,835 shares of the biopharmaceutical company’s stock worth $1,282,000 after purchasing an additional 32,798 shares during the period. United Bank grew its holdings in shares of Pfizer by 2.3% during the 4th quarter. United Bank now owns 59,060 shares of the biopharmaceutical company’s stock worth $2,174,000 after purchasing an additional 1,314 shares during the period. Finally, Berman Capital Advisors LLC grew its holdings in shares of Pfizer by 6.5% during the 4th quarter. Berman Capital Advisors LLC now owns 27,014 shares of the biopharmaceutical company’s stock worth $993,000 after purchasing an additional 1,640 shares during the period. Institutional investors own 64.10% of the company’s stock.
In other news, SVP Jennifer B. Damico sold 2,500 shares of the stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the transaction, the senior vice president now owns 13,748 shares of the company’s stock, valued at $561,193.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.05% of the stock is owned by corporate insiders.
Shares of PFE stock traded up $0.28 on Thursday, hitting $41.30. 244,682 shares of the stock traded hands, compared to its average volume of 20,340,868. The company has a quick ratio of 1.16, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The company has a market cap of $231.18 billion, a P/E ratio of 20.93, a PEG ratio of 1.46 and a beta of 0.74. Pfizer Inc. has a 1-year low of $33.36 and a 1-year high of $43.08. The stock’s fifty day moving average is $39.54.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 4th. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.15. The firm had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $13.41 billion. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. The firm’s revenue was up 44.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.80 EPS. On average, analysts predict that Pfizer Inc. will post 3.71 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 7th. Investors of record on Friday, July 30th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a yield of 3.78%. Pfizer’s payout ratio is currently 70.27%.
Pfizer Inc engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare.
Further Reading: How Do Mutual Funds Work?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.